Altimmune, Inc. (ALT)
| Market Cap | 479.24M |
| Revenue (ttm) | 8.19M |
| Net Income (ttm) | -49.04M |
| Shares Out | 25.64M |
| EPS (ttm) | -1.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $12.74 |
| Previous Close | $12.85 |
| Change ($) | -0.11 |
| Change (%) | -0.86% |
| Day's Open | 12.81 |
| Day's Range | 12.41 - 13.44 |
| Day's Volume | 698,707 |
| 52-Week Range | 4.27 - 35.10 |
GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial result...
Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-CoV-2 challenge model of infection. The resul...
Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alternus Energy Group PLC (NOTC:ALT) named industry veteran Gary Swan as its chief technical officer, as the fast-growing independent power producer expands its footprint across Europe. “Swan will join...
Alternus Energy Group PLC (NOTC:ALT), the fast-growing pan-European independent power producer, announced the recent issuance of €9 million convertible notes lead by AVG Group Sarl, a Luxembourg-based a...
10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...
The short answer: It depends.
Altimmune Inc (NASDAQ: ALT) has reported data from Phase 1b trial evaluating its NasoShield intranasal anthrax vaccine candidate. The 1b trial evaluated the safety and immunogenicity of one and two-dose...
GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine...
Alternus Energy Group PLC (NOTC:ALT), the fast-growing pan-European independent power producer, has announced the completion of the acquisition of two additional solar parks in Romania from Renesola Pow...
Metered Multidose Device Allows for Convenient and Cost-effective Vaccination Metered Multidose Device Allows for Convenient and Cost-effective Vaccination
If you're thinking of investing in this spectacular coronavirus growth stock, now may be too late.
Altimmune Inc. (NASDAQ: ALT) is making headway in the fight against COVID-19 after the firm announced additional preclinical data in regards to its single-dose intranasal vaccine candidate, AdCOVID.
Altimmune Inc (NASDAQ: ALT) has reported additional preclinical data for COVID-19 vaccine candidate, AdCOVID. The data showed that a single intranasal dose of AdCOVID provided 100% protection against th...
Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the sto...
Altimmune Inc (NASDAQ: ALT) has expanded its previously-announced manufacturing collaboration with Lonza Group (OTCMKT: LZAGY) for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate. Under t...
Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune's COVID-19 Vaccine Candidate at its Houston Facility Lonza to Commission a Dedicated Suite for Clinical and Commerci...
Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing internatio...
Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing internatio...
GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a...
Green energy is finally going mainstream, providing predictable long-term returns, with wind and solar power part of the investment megatrend and in this Alternus Energy Group PLC (NOTC:ALT) is particul...
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Nasal spray may offer room temperature distribution that could reduce logistical challenges for healthcare systems and providers
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results o...
The company's COVID-19 program is moving ahead.
Altimmune Inc (NASDAQ: ALT) shares are advancing following an update on its coronavirus vaccine program. What Happened: Maryland-based Altimmune said the FDA has cleared its investigational new drug app...
Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week Enrollment in Phase 1 clinical trial of single-dose, needle-free, ...
No kidding around ... here's how they truly can.
New York, New York--(Newsfile Corp. - January 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are ad...
Transport and storage of their potential vaccines would be a piece of cake.
This biotech just might have what it takes.
They're risky but could deliver huge returns in the new year.
Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.
Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimmune...
GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinationa...
It's down, but not out.
Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52. Altimmune's (ALT) valuation is at a discount after the recent sell-off, and the fu...
Altimmune Inc. (NASDAQ: ALT) shares dropped on Thursday after the company announced that it had received an update from the U.S.
Altimmune, a clinical-stage biopharmaceutical company, fell as much as 10% on Thursday after the FDA issued a clinical hold on the company's COVID-19 vaccine candidate. AdCOVID is a single-dose intranas...
GAITHERSBURG, Md., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issue...
Investors are excited about an analyst's bullish opinion about the biotech stock.
GAITHERSBURG, Md., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer of Altimmune ...
Share price has recently stumbled due to results of the leading vaccines. Vaccine development timeline is way behind the leading vaccines.
Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.
Simple, single-dose nasal spray offers greater ease and comfort of administration ; positioning AdCOVID as a differentiated vaccine candidate for adults and children
GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for live...
Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2020 Results - Earnings Call Transcript
Altimmune Inc. (NASDAQ: ALT) stepped forward on Tuesday with its vaccine candidate for COVID-19.
AdCOVID , a Single-dose Intranasal Vaccine for COVID-19 is Designed to Generate a Broad Immune Response Against COVID-19 with the Unique Ability to Promote Nasal Mucosal Immunity
About ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that i... [Read more...]
| Industry Biotechnology | |
| CEO Vipin Garg | Employees 43 |
| Stock Exchange NASDAQ | Ticker Symbol ALT |
Financial Performance
In 2020, Altimmune's revenue was $8.19 million, an increase of 41.09% compared to the previous year's $5.80 million. Losses were -$49.04 million, 139.0% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Altimmune stock is "Strong Buy." The 12-month stock price forecast is 41.83, which is an increase of 228.34% from the latest price.